Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Do you think this could revolutionize treatment options for obesity and osteoarthritis
Novo Nordisk said that PIONEER TEENS is the first clinical trial of an oral GLP-1 in this age group, and could become an important new option for T2D patients of this age "who require glycaemic control beyond that provided by the current standard of care." There are also limitations with the current treatment options, as metformin is unable to achieve blood glucose control targets in approximately half of adolescents, while basal insulins can have side effects, including low and potentially dangerous blood glucose levels (hypoglycaemia) and weight gain
J., Werler, M
Find articles by Azulai, S
US$ 21.09
US$ 29.55
US$ 23.90
US$ 28.54
